Global Pediatric Clinical Trials Market Size study, By Phase (Phase I, Phase II, Phase III, and Phase IV), By Study Design (Treatment Studies and Observational Studies), By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes an

Global Pediatric Clinical Trials Market Size study, By Phase (Phase I, Phase II, Phase III, and Phase IV), By Study Design (Treatment Studies and Observational Studies), By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes and Other Therapeutic Areas), and Regional Forecasts 2022-2028

Global Pediatric Clinical Trials Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The Pediatric Clinical Trials refers to clinical trials that are designed and conducted specifically for children. Pediatric clinical trials are mainly conducted to study and treat different therapeutic areas in children such as respiratory diseases, infectious diseases, oncology, diabetes. The rising burden of chronic and infectious diseases in pediatric and increasing awareness towards pediatric clinical trials as well as recent funding activities towards pediatric clinical trials are factors that are accelerating the global market demand. For instance, according to American Academy of Pediatrics – as of 2020, around 10 million children and adolescents in the United States are affected by some form of chronic illness or disability. Furthermore, as per World Health Organization (WHO) estimates – as of 2021, every year around 400 000 children and adolescents of 0-19 years affected by cancer. The most prevalent types of childhood cancers include leukemias, brain cancers, lymphomas and solid tumours, such as neuroblastoma and Wilms tumours. Moreover, in high-income countries, more than 80% of children with cancer are cured. Whereas, in low- and middle-income countries (LMICs), only less than 30% are cured. However, recent funding activities from regulatory organizations are likely to influence the growth of pediatric clinical trials. For instance, in May 2022, Australian Government’s Medical Research Future Fund (MRFF) awarded grant of USD 11 million to Five University of Sydney researchers. This funding intended to improve clinical and health outcomes of children affected with juvenile idiopathic arthritis. Also, growing research & development investments by pharmaceutical players and increasing adoption contract research organizations are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, stringent government regulations and cumbersome approval processes impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Pediatric Clinical Trials Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing healthcare spending and presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing pediatric population and surging penetration of Clinical research organization (CROs) in the region, would create lucrative growth prospects for the global Pediatric Clinical Trials Market across the Asia Pacific region.

Major market players included in this report are:
ICON plc

Syneos Health

Medpace, Inc.

PPD Inc.

Premier Research

LabCorp Drug Development

QPS Holdings.

Pfizer Inc.

The Emmes Company, LLC

IQVIA Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Phase
Phase I
Phase II
Phase III
Phase IV
By Study Design
Treatment Studies
Observational Studies
By Therapeutic Area
Respiratory Diseases
Infectious Diseases
Oncology
Diabetes
Other Therapeutic Areas
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Pediatric Clinical Trials Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


Companies Mentioned

ICON plc

Syneos Health

Medpace, Inc.

PPD Inc.

Premier Research

LabCorp Drug Development

QPS Holdings.

Pfizer Inc.

The Emmes Company, LLC

IQVIA Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.